Pathophysiologische Mechanismen der Progression von Nierenerkrankungen

Ngoc Dong Nhi Vo; Gunter Wolf; Ivonne Loeffler

doi:10.1055/a-2536-2719

Nephrologie aktuell, Table of Contents

Nephrologie aktuell 2025; 29(06): 294-307
DOI: 10.1055/a-2536-2719

Schwerpunkt

CME-Fortbildung

Pathophysiologische Mechanismen der Progression von Nierenerkrankungen

Ngoc Dong Nhi Vo

,

Gunter Wolf

,

Ivonne Loeffler

Abstract

Zusammenfassung

Chronische Nierenerkrankungen betreffen mehr als 10 % der Weltbevölkerung und belasten das Gesundheitssystem und den individuellen Patienten erheblich. Um die Pathophysiologie dieser Erkrankungen adäquat zu erfassen, ist ein Verständnis der Mechanismen essenziell. Dieser Beitrag fasst zentrale Mechanismen der Krankheitsprogression zusammen, die bei jeder Nierenerkrankung, unabhängig von ihrer Ätiologie eine zentrale Rolle spielt, und stellt relevante wissenschaftliche Erkenntnisse vor, die für das Verständnis von Bedeutung sind.

Full Text

References

Literatur
1 Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011) 2022; 12: 7-11
2 Eckardt KU, Coresh J, Devuyst O. et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013; 382: 158-169
3 Titze S, Schmid M, Kottgen A. et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant 2015; 30: 441-451
4 Abro A, Greenhall GHB, Nitsch D. Chronic Kidney Disease: Epidemiology and Causes. In: Harber M. Primer on Nephrology. Cham: Springer International Publishing; 2022: 1123-1133
5 Bonsib SM. Renal Vascular Diseases. In: Stephen M, Bonsib MD. Atlas of Medical Renal Pathology. New York: Springer New York; 2013: 147-177
6 Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379: 165-180
7 Jordans I. Bundesverband Niere e. V. Chronische Nierenerkrankungen – Allgemeine Informationen über die Erkrankung. Im Internet: Accessed April 14, 2025 at: https://www.bundesverband-niere.de/informationen/chronische-nierenerkrankungen
8 Kaartinen K, Safa A, Kotha S. et al. Complement dysregulation in glomerulonephritis. Semin Immunol 2019; 45: 101331
9 Floege J, Amann K. Primary glomerulonephritides. Lancet 2016; 387: 2036-2048
10 Shah PP, Brady TM, Meyers KEC. et al. Association of Obesity with Cardiovascular Risk Factors and Kidney Disease Outcomes in Primary Proteinuric Glomerulopathies. Nephron 2021; 145: 245-255
11 Sulaiman MK. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. Diabetol Metab Syndr 2019; 11: 7
12 Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011; 86: 444-456
13 VR ALBVR. Tan SH, Candasamy M. et al. Diabetic nephropathy: An update on pathogenesis and drug development. Diabetes Metab Syndr 2019; 13: 754-762
14 Samsu N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. Biomed Res Int 2021; 2021: 1497449
15 Lopez-Novoa JM, Martinez-Salgado C, Rodriguez-Pena AB. et al. Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. Pharmacol Ther 2010; 128: 61-81
16 Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007; 22: 2011-2022
17 Wolf G, Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 2003; 14: 1396-1405
18 Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997; 29: 153-163
19 Chen S, Wolf G, Ziyadeh FN. The renin-angiotensin system in diabetic nephropathy. Contrib Nephrol 2001; 212-221
20 Wolf G, Mueller E, Stahl RA. et al. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993; 92: 1366-1372
21 Wolf G, Ziyadeh FN, Stahl RA. Angiotensin II stimulates expression of transforming growth factor beta receptor type II in cultured mouse proximal tubular cells. J Mol Med (Berl) 1999; 77: 556-564
22 Wolf G, Zahner G, Schroeder R. et al. Transforming growth factor beta mediates the angiotensin-II-induced stimulation of collagen type IV synthesis in cultured murine proximal tubular cells. Nephrol Dial Transplant 1996; 11: 263-269
23 Wolf G, Wenzel U, Burns KD. et al. Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int 2002; 61: 1986-1995
24 Wolf G, Bohlender J, Bondeva T. et al. Angiotensin II upregulates toll-like receptor 4 on mesangial cells. J Am Soc Nephrol 2006; 17: 1585-1593
25 Huang R, Fu P, Ma L. Kidney fibrosis: from mechanisms to therapeutic medicines. Signal Transduct Target Ther 2023; 8: 129
26 Duffield JS. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 2014; 124: 2299-2306
27 Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011; 7: 684-696
28 Vanhove T, Goldschmeding R, Kuypers D. Kidney Fibrosis: Origins and Interventions. Transplantation 2017; 101: 713-726
29 Matovinovic MS. 1. Pathophysiology and Classification of Kidney Diseases. EJIFCC 2009; 20: 2-11
30 Noronha IL, Fujihara CK, Zatz R. The inflammatory component in progressive renal disease–are interventions possible?. Nephrol Dial Transplant 2002; 17: 363-368
31 Yamashita N, Kramann R. Mechanisms of kidney fibrosis and routes towards therapy. Trends Endocrinol Metab 2024; 35: 31-48
32 Wu D, Wu J, Liu H. et al. A biomimetic renal fibrosis progression model on-chip evaluates anti-fibrotic effects longitudinally in a dynamic fibrogenic niche. Lab Chip 2023; 23: 4708-4725
33 Loeffler I, Wolf G. Transforming growth factor-beta and the progression of renal disease. Nephrol Dial Transplant 2014; 29 (Suppl. 1) i37-i45
34 Fu H, Tian Y, Zhou L. et al. Tenascin-C Is a Major Component of the Fibrogenic Niche in Kidney Fibrosis. J Am Soc Nephrol 2017; 28: 785-801
35 Li L, Fu H, Liu Y. The fibrogenic niche in kidney fibrosis: components and mechanisms. Nat Rev Nephrol 2022; 18: 545-557
36 Yuan Q, Tan RJ, Liu Y. Myofibroblast in Kidney Fibrosis: Origin, Activation, and Regulation. In: Liu B-C, Lan H-Y, Lv L-L. et al. Renal Fibrosis: Mechanisms and Therapies. Singapore: Springer Singapore; 2019: 253-283
37 Herrera J, Henke CA, Bitterman PB. Extracellular matrix as a driver of progressive fibrosis. J Clin Invest 2018; 128: 45-53
38 McWilliam SJ, Wright RD, Welsh GI. et al. The complex interplay between kidney injury and inflammation. Clin Kidney J 2021; 14: 780-788
39 Ernandez T, Mayadas TN. The Changing Landscape of Renal Inflammation. Trends Mol Med 2016; 22: 151-163
40 Tecklenborg J, Clayton D, Siebert S. et al. The role of the immune system in kidney disease. Clin Exp Immunol 2018; 192: 142-150
41 Andrade-Oliveira V, Foresto-Neto O, Watanabe IKM. et al. Inflammation in Renal Diseases: New and Old Players. Front Pharmacol 2019; 10: 1192
42 Panzer U, Steinmetz OM, Stahl RA. et al. Kidney diseases and chemokines. Curr Drug Targets 2006; 7: 65-80
43 Salvadori M, Tsalouchos A. Microbiota, renal disease and renal transplantation. World J Transplant 2021; 11: 16-36
44 Cao C, Zhu H, Yao Y. et al. Gut Dysbiosis and Kidney Diseases. Front Med (Lausanne) 2022; 9: 829349
45 Chi M, Ma K, Wang J. et al. The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease. J Immunol Res 2021; 2021: 5516035
46 Snelson M, Biruete A, McFarlane C. et al. A Renal Clinician’s Guide to the Gut Microbiota. J Ren Nutr 2020; 30: 384-395
47 Mihai S, Codrici E, Popescu ID. et al. Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome. J Immunol Res 2018; 2018: 2180373
48 Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 2013; 83: 1010-1016
49 Krishnan S, Suarez-Martinez AD, Bagher P. et al. Microvascular dysfunction and kidney disease: Challenges and opportunities?. Microcirculation 2021; 28: e12661
50 Schlondorff DO. Overview of factors contributing to the pathophysiology of progressive renal disease. Kidney Int 2008; 74: 860-866
51 Adamczak M, Zeier M, Dikow R. et al. Kidney and hypertension. Kidney Int Suppl 2002; 62-67
52 Udani S, Lazich I, Bakris GL. Epidemiology of hypertensive kidney disease. Nat Rev Nephrol 2011; 7: 11-21
53 Mullins LJ, Conway BR, Menzies RI. et al. Renal disease pathophysiology and treatment: contributions from the rat. Dis Model Mech 2016; 9: 1419-1433
54 London GM. Arterial Stiffness in Chronic Kidney Disease and End-Stage Renal Disease. Blood Purif 2018; 45: 154-158
55 Dusing P, Zietzer A, Goody PR. et al. Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. J Mol Med (Berl) 2021; 99: 335-348
56 Toussaint ND, Kerr PG. Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. Nephrology (Carlton) 2007; 12: 500-509
57 Inserra F, Forcada P, Castellaro A. et al. Chronic Kidney Disease and Arterial Stiffness: A Two-Way Path. Front Med (Lausanne) 2021; 8: 765924
58 Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004; 44: 595-601
59 Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one, more the other?. Am J Hypertens 1988; 1: 335-347
60 Gross ML, Amann K. Progression of renal disease: new insights into risk factors and pathomechanisms. Curr Opin Nephrol Hypertens 2004; 13: 307-312
61 Singh GR, Hoy WE. Kidney volume, blood pressure, and albuminuria: findings in an Australian aboriginal community. Am J Kidney Dis 2004; 43: 254-259
62 Fassi A, Sangalli F, Maffi R. et al. Progressive glomerular injury in the MWF rat is predicted by inborn nephron deficit. J Am Soc Nephrol 1998; 9: 1399-1406
63 Keller G, Zimmer G, Mall G. et al. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348: 101-108
64 Reyes L, Manalich R. Long-term consequences of low birth weight. Kidney Int Suppl 2005; S107–111
65 Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000; 35: S97-105
66 Chang A, Ko K, Clark MR. The emerging role of the inflammasome in kidney diseases. Curr Opin Nephrol Hypertens 2014; 23: 204-210
67 Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2-15
68 Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage?. J Am Soc Nephrol 2006; 17: 2974-2984
69 Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007; 106: 26-31
70 Komada T, Muruve DA. The role of inflammasomes in kidney disease. Nat Rev Nephrol 2019; 15: 501-520
71 Aranda-Rivera AK, Srivastava A, Cruz-Gregorio A. et al. Involvement of Inflammasome Components in Kidney Disease. Antioxidants (Basel) 2022; 11
72 Zhuang Y, Ding G, Zhao M. et al. NLRP3 inflammasome mediates albumin-induced renal tubular injury through impaired mitochondrial function. J Biol Chem 2014; 289: 25101-25111
73 Fang L, Xie D, Wu X. et al. Involvement of endoplasmic reticulum stress in albuminuria induced inflammasome activation in renal proximal tubular cells. PLoS One 2013; 8: e72344
74 Zhou R, Yazdi AS, Menu P. et al. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469: 221-225
75 Hsu CN, Tain YL. Developmental Origins of Kidney Disease: Why Oxidative Stress Matters?. Antioxidants (Basel) 2020; 10
76 Small DM, Coombes JS, Bennett N. et al. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton) 2012; 17: 311-321
77 Krata N, Zagozdzon R, Foroncewicz B. et al. Oxidative Stress in Kidney Diseases: The Cause or the Consequence?. Arch Immunol Ther Exp (Warsz) 2018; 66: 211-220
78 Tejchman K, Kotfis K, Sienko J. Biomarkers and Mechanisms of Oxidative Stress-Last 20 Years of Research with an Emphasis on Kidney Damage and Renal Transplantation. Int J Mol Sci 2021; 22: 8010
79 Piko N, Bevc S, Hojs R. et al. The Role of Oxidative Stress in Kidney Injury. Antioxidants (Basel) 2023; 12: 1772
80 Duann P, Lin PH. Mitochondria Damage and Kidney Disease. Adv Exp Med Biol 2017; 982: 529-551
81 Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol 2007; 18: 2439-2446
82 Ozbek E. Induction of oxidative stress in kidney. Int J Nephrol 2012; 2012: 465897
83 Ho HJ, Shirakawa H. Oxidative Stress and Mitochondrial Dysfunction in Chronic Kidney Disease. Cells 2022; 12: 88
84 Pedraza-Chaverri J, Sanchez-Lozada LG, Osorio-Alonso H. et al. New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease. Oxid Med Cell Longev 2016; 2016: 6043601
85 Honda T, Hirakawa Y, Nangaku M. The role of oxidative stress and hypoxia in renal disease. Kidney Res Clin Pract 2019; 38: 414-426
86 Wang Y, Chen X, Song Y. et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008; 73: 19-33
87 Vupputuri S, Sandler DP. Lifestyle risk factors and chronic kidney disease. Ann Epidemiol 2003; 13: 712-720
88 Wolf G, Chen S, Han DC. et al. Leptin and renal disease. Am J Kidney Dis 2002; 39: 1-11
89 Wolf G. After all those fat years: renal consequences of obesity. Nephrol Dial Transplant 2003; 18: 2471-2474
90 Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol 2013; 33: 14-22
91 Ruster C, Wolf G. Adipokines promote chronic kidney disease. Nephrol Dial Transplant 2013; 28 (Suppl. 4) iv8-14
92 Wolf G, Hamann A, Han DC. et al. et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [seecomments]. Kidney Int 1999; 56: 860-872
93 Han DC, Isono M, Chen S. et al. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression. Kidney Int 2001; 59: 1315-1323
94 Hallan SI, Orth SR. Smoking is a risk factor in the progression to kidney failure. Kidney Int 2011; 80: 516-523
95 Orth SR. Smoking--a renal risk factor. Nephron 2000; 86: 12-26
96 Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol 2006; 164: 263-271